Cargando…

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

BACKGROUND: Median survival is 10 months and 2-year survival is 20% in metastatic non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. A small fraction of non-squamous cell lung cancers harbor EGFR mutations, with improved outcome to gefitinib and erlotinib. Experimental evid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosell, Rafael, Perez-Roca, Laia, Sanchez, Jose Javier, Cobo, Manuel, Moran, Teresa, Chaib, Imane, Provencio, Mariano, Domine, Manuel, Sala, Maria Angeles, Jimenez, Ulpiano, Diz, Pilar, Barneto, Isidoro, Macias, Jose Antonio, de las Peñas, Ramon, Catot, Silvia, Isla, Dolores, Sanchez, Jose Miguel, Ibeas, Rafael, Lopez-Vivanco, Guillermo, Oramas, Juana, Mendez, Pedro, Reguart, Noemi, Blanco, Remei, Taron, Miquel
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673583/ https://www.ncbi.nlm.nih.gov/pubmed/19415121 http://dx.doi.org/10.1371/journal.pone.0005133

Ejemplares similares

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
por: Provencio, Mariano, et al.
Publicado: (2022)

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
por: Arriola, Edurne, et al.
Publicado: (2018)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
por: Isla, Dolores, et al.
Publicado: (2023)

BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2007)

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2020)

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
por: Simonetti, Sara, et al.
Publicado: (2010)

Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening
por: Rosell, Rafael, et al.
Publicado: (2015)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
por: Provencio, Mariano, et al.
Publicado: (2022)

Are there differences by sex in lung cancer characteristics at diagnosis? —a nationwide study
por: Ruano-Ravina, Alberto, et al.
Publicado: (2021)

Kisspeptins and norepinephrine regulate different G-protein-coupled receptor signaling pathways
por: Rosell, Rafael, et al.
Publicado: (2022)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
por: Chaib, Imane, et al.
Publicado: (2017)

Lung cancer symptoms at diagnosis: results of a nationwide registry study
por: Ruano-Raviña, Alberto, et al.
Publicado: (2020)

Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
por: Arriola, Edurne, et al.
Publicado: (2022)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
por: Sierra-Rodero, Belén, et al.
Publicado: (2021)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Prevalencia y severidad de la disfunción intestinal inducida por opioides()
por: Gálvez, Rafael, et al.
Publicado: (2014)

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
por: Gutiérrez, Lourdes, et al.
Publicado: (2021)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
por: Serna-Blasco, Roberto, et al.
Publicado: (2022)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer
por: de Aguirre, Itziar, et al.
Publicado: (2006)

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
por: Codony-Servat, Carles, et al.
Publicado: (2017)

Detecting ALK , ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA‐based techniques
por: Giménez‐Capitán, Ana, et al.
Publicado: (2023)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
por: Karachaliou, Niki, et al.
Publicado: (2018)

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
por: Franco, Fernando, et al.
Publicado: (2021)

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2018)

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2019)

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
por: Bonanno, Laura, et al.
Publicado: (2013)

Changes in Gene Expression Associated with Collagen Regeneration and Remodeling of Extracellular Matrix after Percutaneous Electrolysis on Collagenase-Induced Achilles Tendinopathy in an Experimental Animal Model: A Pilot Study
por: Sánchez-Sánchez, José Luis, et al.
Publicado: (2020)

Cadaveric and Ultrasound Validation of Percutaneous Electrolysis Approach at the Achilles Tendon as a Potential Treatment for Achilles Tendinopathy: A Pilot Study
por: Calderón-Díez, Laura, et al.
Publicado: (2022)

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
por: Bonanno, Laura, et al.
Publicado: (2016)

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
por: Margeli, Mireia, et al.
Publicado: (2010)

Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
por: García-Campelo, Rosario, et al.
Publicado: (2023)

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
por: García-Campelo, Rosario, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vb39ssctjd6gr1ne3b641forpl